DNASE2

Across TCGA pan-cancer cohorts, DNASE2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNASE2 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher DNASE2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNASE2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

READ, SKCM, and STAD are the cancer types where DNASE2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
SKCM	DFS	Median	III,IV	0.126	0.615	.002	18	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
PRAD	DFS	Median	All	0.118	0.886	<.001	6	view →
BLCA	DFS	Median	IV	1.000	0.195	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNASE2–READ (OS)

Open the READ breakdown →